Bevacizumab

Abstract

Various toxicities: 4 case reportsIn a retrospective study of 98 patients with newly diagnosed ovarian, fallopian tube or primary peritoneal cancers treated from January 2017 to December 2018, 4 women aged 42-58 years * were described, who developed vesicovaginal fistula, symptoms of subileus, ileus, headache or tachycardia during treatment with bevacizumab for an unspecified cancer.The women, who had an unspecified cancer, started receiving bevacizumab [dosages and routes not stated]. Subsequently, the women developed vesicovaginal fistula (1 woman), symptoms of subileus (1 woman), ileus (1 woman), and headache and tachycardia (1 woman) [durations of treatments to reactions onsets not stated].Bevacizumab was stopped in the women who had vesicovaginal fistula, symptoms of subileus or ileus. The woman, who had ileus, was hospitalised and was scheduled for an unspecified surgery to treat the ileus [outcomes not stated].* Identifying patient details (age and sex) have been obtained through direct communication with the author.